摘要
目的探讨肾移植术后免疫抑制剂引起肝功能损害的治疗措施。方法对32例肾移植术后出现肝功能异常的病例进行分析,观察肝功能指标以及CsA浓度,及时调整免疫抑制剂,配合保肝治疗。结果CsA+MMF+Pred发生率22.9%,CsA+Aza+Pred发生率31.3%,FK506+MMF+Pred无1例发生肝功能损害。结论CsA+MMF+Pred、FK506+MMF+Pred是目前较为理想的免疫抑制治疗方案,低剂量CsA可减少肝毒性的发生。
[Objective] To investigate the treatment of hepatic injury caused by immunosuppressant. [Methods] 32 cases with hepatic dysfunction after renal transplantation were analyzed. Hepatic function and cyclosporine concentration were monitored and the dosages of immunosuppressant were adjusted according to the eycloapofine concentrat/on in order to protect liver function. [Results] The incidence of hepatic dysfunction was 22.9% in patients who took CsA＋MMF＋ Pred administration, whereas the incidence was 31.3% in patients who took CsA＋Aza＋ Pred administration. There was no case for hepatic dysfunction in patients who took FK.506＋MMF＋Pred administration. [Conclusion] CsA＋MMF＋ Pred and FKS06＋MMF＋ Pred are ideal treatment after renal transplantation, and low CsA concentration can decrease the incidence of hepatic dysfunction.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2006年第7期1099-1100,1103,共3页
China Journal of Modern Medicine
关键词
肾移植
肝损害
免疫抑制剂
renal transplantation
hepatic injury
immunosuppressant
